Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
(2R,6R)-HNK in Treatment-Resistant Depression
NCT06511908Phase 2Recruiting
- Sponsor
- National Institute of Mental Health
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of (2R,6R)-hydroxynorketamine in treatment-resistant depression (TRD), sponsored by National Institute of Mental Health. Started Nov 2024; status: recruiting.
02
Drugs
(2R,6R)-hydroxynorketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06511908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511908.